• Ralph L Millett, Jacob M Elkon, and Imad A Tabbara.
• GW Cancer Center & Department of Internal Medicine, George Washington University School of Medicine, Washington, DC, U.S.A.
• Anticancer Res. 2018 Sep 1; 38 (9): 4969-4975.

AbstractAnaplastic lymphoma kinase (ALK) rearrangements were first implicated as driving mutations in non-small cell lung cancer in 2007. Since then, a number of novel, small-molecule inhibitors directed against the ALK receptor have demonstrated superiority over standard chemotherapies in the treatment of ALK rearrangement-positive lung cancer. Of considerable importance when considering such therapies is the ability of each to overcome mutations conferring acquired resistance, as well as penetrate the central nervous system (CNS), the most common site of metastasis and traditionally the most difficult to breach. Herein is a review of the efficacy, indications, and degree of CNS penetration for the ALK-targeting agents crizotinib, ceretinib, alectinib, brigatinib, and lorlatinib, as well as a summary of ongoing clinical trials comparing these drugs.Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

53 keywords...

hide…